Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro.

MLA

Nerreter, Thomas, et al. “Combining Dasatinib with Dexamethasone Long-Term Leads to Maintenance of Antiviral and Antileukemia Specific Cytotoxic T Cell Responses in Vitro.” Experimental Hematology, vol. 41, no. 7, July 2013, p. 604. EBSCOhost, https://doi.org/10.1016/j.exphem.2013.02.013.

APA

Nerreter, T., Distler, E., Köchel, C., Einsele, H., Herr, W., & Seggewiss-Bernhardt, R. (2013). Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro. Experimental Hematology, 41(7), 604. https://doi.org/10.1016/j.exphem.2013.02.013

Chicago

Nerreter, Thomas, Eva Distler, Carolin Köchel, Hermann Einsele, Wolfgang Herr, and Ruth Seggewiss-Bernhardt. 2013. “Combining Dasatinib with Dexamethasone Long-Term Leads to Maintenance of Antiviral and Antileukemia Specific Cytotoxic T Cell Responses in Vitro.” Experimental Hematology 41 (7): 604. doi:10.1016/j.exphem.2013.02.013.